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Summary
Sevuparin is a novel drug candidate in phase II development as a treatment
for vaso-occlusive crises (VOC) in patients with sickle cell disease (SCD). As
a heparin-derived polysaccharide, sevuparin has been designed to retain anti-
adhesive properties, while the antithrombin-binding domains have been
eliminated, substantially diminishing its anticoagulant activity. Here, we
demonstrate that sevuparin inhibits the adhesion of human sickle red blood
cells (SS-RBCs) to stimulated cultured endothelial cells in vitro. Importantly,
sevuparin prevents vaso-occlusion and normalizes blood flow in an in vivo
mouse model of SCD vaso-occlusion. Analyses by surface plasmon resonance
(SPR) and fluorescence correlation spectroscopy (FCS) demonstrate that
sevuparin binds to P- and L-selectins, thrombospondin, fibronectin and von
Willebrand factor, all of which are thought to contribute to vaso-occlusion
in SCD. Despite low anticoagulation activity, sevuparin has anti-adhesive
efficacy similar to the low molecular weight heparin tinzaparin both in vitro
and in vivo. These results suggest that the anti-adhesive properties rather
than the anticoagulant effects of heparinoids are critical for the treatment of
vaso-occlusion in SCD. Therefore, sevuparin is now being evaluated in SCD
patients hospitalized for treatment of VOC.
Keywords: sickle cell disease, cell adhesion, adhesion receptors, vaso-
occlusion, heparinoids.
Sickle cell disease (SCD) is the most common
haemoglobinopathy, affecting millions of people worldwide
(Weatherall, 2010). A single point mutation in the sixth codon
of the b-globin gene (HBB) results in the synthesis of abnor-
mal sickle haemoglobin (HbS), which polymerizes and causes
red blood cell (RBC) deformation (‘sickling’) under hypoxic
conditions. RBCs containing predominantly HbS (SS-RBCs)
also demonstrate an adhesive phenotype, (Hebbel et al, 1980a)
and the degree of adhesiveness is correlated with vaso-occlu-
sive crisis (VOC) frequency (Hebbel et al, 1980b). Vaso-occlu-
sion, the pathognomonic finding of SCD, involves binding of
blood cells to the endothelium. SS-RBCs adhere to and acti-
vate endothelial cells and leucocytes, and also stimulate coagu-
lation (Kaul & Hebbel,2000; Brown et al, 2001; Zennadi et al,
2007, 2008; Ataga et al, 2012). Hypoxia/reperfusion injury also
results in leucocyte activation, chronic and acute inflamma-
tion, and endothelial activation and damage (Frenette, 2002).
All of these events, particularly the adhesiveness of both leuco-
cytes and SS-RBCs to endothelial receptors, contribute to
VOC (Manwani & Frenette, 2013), the most common clinical
consequence of SCD with the exception of chronic haemolytic
anaemia.
Pain is a hallmark of SCD (de Montalembert, 2008; Stein-
berg, 2011; Ballas & Darbari, 2013), can be acute or chronic,
and is most often located in the back, chest, joints and the
long bones of the extremities. VOC presents as acute pain
that can last for several days to a week or more (de Mon-
talembert, 2008; Steinberg, 2011). The frequency and severity
of such painful episodes vary among patients (de Montalem-
bert, 2008; Steinberg, 2011).
The initial attachment of SS-RBCs to the vessel wall has
previously been demonstrated to be mediated by very short-
lived interactions via selectins (Matsui et al, 2001, 2002; Bur-
nette et al, 2011; Gutsaeva et al, 2011; Kutlar et al, 2012).
Following further cascade activation, firm attachment of SS-
RBCs and leucocytes occurs mainly via interactions with
integrins, causing subsequent vessel obstruction (Kaul et al,
2000, 2006; Zennadi et al, 2004, 2007, 2008; Finnegan et al,
2007a). P-selectin contributes to SS-RBC adhesion and vaso-
occlusion both in vitro and in vivo (Matsui et al, 2001, 2002;
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Embury et al, 2004; Burnette et al, 2011). P-selectin blockade
can improve blood flow and can decrease serum markers of
disease in patients with SCD (Kutlar et al, 2012). In addition,
E-selectin is upregulated during inflammatory processes
(Ebnet & Vestweber, 1999; Parent & Eichacker, 1999; Langer
& Chavakis, 2009) and participates in white blood cell adhe-
sion in SCD (Turhan et al, 2002; Zennadi et al, 2008). How-
ever, as E-selectin is also an important immune component
in response to infections, blocking E-selectin could theoreti-
cally be detrimental in infection-induced VOC. L-selectin
contributes to lymphocyte and neutrophil trafficking and is
cleaved from leucocytes during activation. Children with
SCD and a history of silent cerebral infarct (SCI) have signif-
icantly higher soluble L-selectin levels than non-SCI patients,
(Faulcon et al, 2013) suggesting that increased inflammatory
responses may be associated with disease severity (Kinney
et al, 1999; Faulcon et al, 2013). Although not yet demon-
strated, blockade of adhesive interactions via L-selectin could
be beneficial in SCD, especially in this group.
While cell-cell interactions between SS-RBCs and the
endothelium are necessary for VOC to occur, VOC pathogene-
sis also involves endothelial cell activation and changes in the
levels of various plasma proteins (Pathare et al, 2003; Finnegan
et al, 2007b; Sparkenbaugh & Pawlinski, 2013). Several non-
membrane bound proteins, such as von Willebrand factor
(VWF) (Krishnan et al, 2008; Zhou et al, 2009; Chen et al,
2011) and thrombospondin (TSP) (Brittain et al, 1993, 2001a,
b; Novelli et al, 2012), may contribute by serving as anchoring
or bridging proteins, and several of these proteins have hep-
arin-binding sites. Furthermore, both heparin and low molec-
ular weight heparins (LMWHs) can bind to several adhesion
proteins (Koenig et al, 1998; Gupta et al, 1999; Polanowska-
Grabowska et al, 2010; Burnette et al, 2011) to inhibit SS-RBC
adhesion (Barabino et al, 1999; Matsui et al, 2001, 2002;
Gayen Betal & Setty, 2008) and to restore blood flow in animal
models of SCD (Embury et al, 2004).
In a clinical study of patients with SCD who were experi-
encing acute VOC, treatment with anti-thrombotic doses of
the LMWH, tinzaparin, resulted in significant reductions in
VOC duration, the number of days with severe pain and
hospitalization duration (Qari et al, 2007). However, bleed-
ing events required treatment cessation in some patients
(Qari et al, 2007). Thus, while heparins and LMWHs have
anti-adhesive and anti-inflammatory properties, as well as
anticoagulant effects, all of which are potentially beneficial in
VOC treatment, the associated risk of bleeding has slowed
further clinical testing of heparinoids in SCD patients (Lever
& Page, 2002; Qari et al, 2007; Shah et al, 2013).
Sevuparin (DF02) is a novel drug candidate currently in
early phase development for VOC treatment in patients
with SCD and parsite caused RBC adhesion in malaria
(NCT02515838 and NCT01442168, respectively). Sevuparin
is a negatively charged polysaccharide derived from heparin
through chemical depolymerization, in which the specific
pentasaccharide that is involved in high-affinity binding to
antithrombin III is deleted. As a result, sevuparin has no
direct effect on factor Xa nor on thrombin, and the effect on
the activated partial thromboplastin time (aPTT) is markedly
reduced in comparison with heparin and LMWH (Lindgren
et al, 2015). Here, we demonstrate the binding characteristics
of sevuparin with proteins involved in SCD vaso-occlusion
and provide evidence of the pronounced anti-adhesive prop-
erties of this new potential treatment. Finally, we demon-
strate that sevuparin improves blood flow in an in vivo
model of VOC, likely through a multi-factorial mechanism
of action involving several adhesion proteins.
Materials and methods
Sevuparin
Sevuparin, like other members of the chemical class of hep-
arins, is polydisperse, encompassing a range of polysaccha-
ride chain lengths. Sevuparin chains range in molecular
weight from 12 to 15 kDa. The predominant size is 6–16
disaccharide units of 2-N-sulfo-6-O-sulfo-glucosamine and
iduronic-2-O-sulfate acid, which corresponds to molecular
weights of 36–96 kDa. The average molecular weight is
approximately 8 kDa. The predominant chemical structure
of sevuparin is illustrated in Fig 1. Sevuparin does not con-
tain the specific binding sequence for antithrombin; as a con-
sequence it has minimal anti-Xa and anti-IIa activity
compared to other heparinoids (Table SI in Data S1).
Synthesis of fluorescein-labelled sevuparin
For direct interaction measurements with target proteins by
fluorescence correlation spectroscopy (FCS), fluorescein-
labelled sevuparin was purchased from EMC Microcollections
GmbH (T€ubingen, Germany), which performed sevuparin
labelling via its free carboxy groups using standard ethylene-
di-carbodiimide coupling.
Surface plasmon resonance measurements
Surface plasmon resonance biosensor technology (SPR, Bia-
core, GE Healthcare, Diegem, Belgium) was used to compare
the interactions of sevuparin, LMWH (tinzaparin) and full-
length heparin. P-, E-, and L-selectin Fc chimeras (R&D Sys-
tems, Minneapolis, MN, USA) were attached via anti-Fc anti-
bodies to the sensor chip, and binding of sevuparin from
solution to the immobilized selectins was recorded in real
time. The data were subjected to both one-site and two-site
binding non-linear analysis in GraphPad Prism (GraphPad
Software, Inc., La Jolla, CA, USA).
Fluorescence correlation spectroscopy
Fluorescence correlation spectroscopy autocorrelation mea-
surements employed the FCS unit of a Leica TCS SP5
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confocal microscope equipped with an HCX PL APO
63 9 N.A. 12 water immersion lens (Leica Microsystems,
Mannheim, Germany). Autocorrelation functions were anal-
ysed using ISS VISTA software (http://www.iss.com/mi-
croscopy/software/vistavision.html). Fitting was performed
according to a 3D-Gaussian diffusion model, assuming two
diffusing components and a triplet component. The fractions
of bound and free ligand were obtained from the fractional
contributions of the slow and fast diffusing components of
the autocorrelation functions (Mader et al, 2004). The parti-
cle number obtained from the fit was corrected for uncorre-
lated background (Eq. 1), (Koppel, 1974)
Gtotð0Þ ¼ 1þ 1=Napp ¼ 1þ ð1 CPSb=CPStÞ2=Ncorr ð1Þ
where CPSt is the total signal (counts per second), CPSb is
the background signal, Napp is the apparent particle number
obtained from the fit to the autocorrelation function and
Ncorr is the corrected particle number. The ratio of total flu-
orescence divided by the number of particles gives the counts
per molecule (CPM), which is the measure of the average
brightness of each particle. The CPM as a measure of molec-
ular brightness was then determined according to (Eq. 2).
CPM ¼ ðCPSt  CPSbÞ=Ncorr ð2Þ
RBC collection and preparation
Blood samples from patients who were homozygous for Hb S
were collected into citrate tubes according to an Institutional
Review Board (IRB)-approved protocol. Blood samples were
collected without regard for presence of absence of hydroxy-
carbamide (also termed hydroxyurea) therapy; donors were
excluded if they had experienced vaso-occlusion within the
preceding 3 weeks or had been transfused within the last
3 months. RBCs were washed in phosphate-buffered saline
(PBS, pH 74), and the plasma and buffy coat were removed.
In vitro adhesion assays
RBC adhesion assays were performed in a graduated height
flow chamber as described previously (Zennadi et al, 2004).
RBCs were labelled with a PKH-26 red fluorescent cell linker
kit (Sigma, St. Louis, MO, USA) following the
manufacturer’s instructions before adhesion assays. Confluent
human umbilical vein endothelial cells (HUVECs) were
grown and prepared on glass slides that had been coated
with 2% gelatin (Sigma). P-selectin expression was induced
by treating HUVECs with 50 ng/ml interleukin (IL) 13
(R&D Systems) for 48 h in culture medium without heparin
(EGM-2, Clonetics, Walkersville, MD, USA) at 37°C and 5%
CO2, washing with PBS++ (PBS with Ca
2+ and Mg2+) and
stimulating with histamine (100 lmol/l, Sigma) in PBS++
for 10 min at 37°C (see Data S1). For inhibition experi-
ments, slides were incubated for 20 min at 37°C with sevu-
parin, antibodies or tinzaparin, washed again, and then
mounted in the flow chamber. An RBC suspension (005%)
was infused at a constant flow rate, determined by the
heights measured in the adjustable flow chamber, to achieve
the desired range of shear stresses (03–5 dynes/cm2). After
RBCs had been infused through the chamber for 2 min,
adhesion events were counted for 2 min at each of seven dif-
ferent locations along the length of the slide during continu-
ous flow. Events counted included both transient and
permanent adhesion, and each field counted was 025 mm2
in area. The number of adhesion events was then calculated
as cells/mm2 at various shear stresses, and the shear stress at
each point inside the flow chamber was calculated as previ-
ously described (Zennadi et al, 2004).
Mouse model of human sickle RBC adhesion and vaso-
occlusion
Adhesive events and vaso-occlusion were studied in an adop-
tive nude mouse (Jackson Laboratories, Bar Harbor, ME,
USA) model. In this model, infused human SS-RBCs cause
vaso-occlusion, which is directly observed in subcutaneous
vessels through implanted window chambers, as previously
described in detail (Zennadi et al, 2007, 2012; Zennadi,
2014). This model has the advantage of using human SS-
RBCs. Murine SS-RBCs lack several human RBC adhesion
molecules, including the laminin receptor basal cell adhesion
molecule/Lutheran antigen (BCAM/Lu, CD239) and the mul-
tifunctional receptor involved in RBC-leucocyte adhesion,
CD44. The role of activation of red cell adhesion receptors
may also be different (Trinh-Trang-Tan et al, 2010). In our
adoptive model, a minority population of human SS-RBCs
causes vaso-occlusion comparable to vaso-occlusion occur-
ring in transfused SCD patients; moreover, we have shown
Fig 1. Chemical structure of sevuparin. The
diagram represents the predominant chemical
structure of sevuparin with the main monosac-
charide constituents. Sevuparin is a polysaccha-
ride-based drug that is designed to retain the
anti-adhesive properties of heparin. The mean
molecular weight of sevuparin is approximately
8 kDa.
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that these events also include adhesion of (murine) leuco-
cytes, as they are believed to do in human illness (Zennadi
et al, 2008). Finally, studies of inhibitors of signalling path-
ways important in vaso-occlusion suggest that findings using
this adoptive model are well-replicated using sickle cell
mouse models (Zennadi, 2014; Zhao et al, 2016).
Dil (Molecular Probes, Thermo Fisher Scientific, Waltham,
MA USA) dye was used to label SS-RBCs. A window chamber
consisting of a double-sided titanium frame was surgically
implanted into the dorsal skinfold of each mouse, and animals
were allowed to recover for 3-5 days to allow healing. To
upregulate endothelial selectin expression and to promote SS-
RBC adhesion and vaso-occlusion, 500 ng murine tumour
necrosis factor a (TNFa; Peprotech, Rocky Hill, NJ, USA) in
100 ll saline was injected intraperitoneally (i.p.) 4 h before
SS-RBC infusion. Generally, an aliquot from each patient sam-
ple was infused into three to five mice to allow for meaningful
comparisons between treatments (e.g. sevuparin or tinzaparin)
and control [sham (saline) treatment], due to the fact that the
degree of adhesion is variable among patients. Thus, conclu-
sions about per cent inhibition of adhesion always included a
control experiment utilizing the same SS-RBCs as were used
for animals receiving an adhesion inhibitor.
The extent of SS-RBC adhesion was determined and
expressed as % vessel occupancy. The sum of vessel lengths
along which there were adherent SS-RBCs was divided by the
total vessel length examined and is presented as % SS-RBC
occupancy for each vessel. All measurable venules were anal-
ysed, and at least 30 vessels for each mouse were measured.
The average of these values represented the overall percentage
of SS-RBC vessel occupancy in an individual mouse.
All measured vessels were also classified for blood flow
status. Vessels were categorized into one of three categories:
normal flowing, non-flowing or slow (or intermittent) flow-
ing. Total vessel lengths in each category were summed for
each mouse (from 4–5 movies), and the percentage was cal-
culated by the total length of each category divided by the
total length of vessels analysed in all three categories.
The degree of adhesion (% vessel occupancy) and vaso-
occlusion (% of vessels with retarded or absent flow) associ-
ated with each treatment were first aggregated for multiple
observed vessels with the same patient sample and animal.
These data were then aggregated among patient samples. The
data were compared using GraphPad Prism 4 software using a
paired Student’s t-test, one-way analysis of variance (ANOVA)
and Tukey’s multiple comparisons test. Specific comparisons
between two treatments were performed using unpaired
t-tests. A P-value <005 was considered to be significant.
Results
Selectin binding by sevuparin
Heparinoids have been associated with inhibition of P-selec-
tin-mediated SS-RBC adhesion in SCD (Matsui et al, 2001;
Embury et al, 2004; Kutlar et al, 2012). Therefore, an initial
experiment was performed to investigate sevuparin’s selectin
binding profile in comparison to LMWH and full-length
heparin. The sevuparin-selectin interactions were studied by
using surface plasmon resonance (SPR) and selectin chi-
meras in which the selectin ectodomain was combined with
an immunoglobulin Fc domain (Scheffler et al, 1995). As
sevuparin consists of long carbohydrate chains, it contains
several potential binding sites; thus, more than one P-selec-
tin chimera may interact with one sevuparin molecule.
Multivalent binding of sevuparin was supported by analysis
of the dose-response function of the binding reaction.
Assuming a two-site binding model increased the quality of
the fit compared with a one-site model. Using a two-site
binding model for data analysis, the corresponding dissocia-
tion constants (Kd) were calculated as 0022 and 16 lmol/l
for heparin, 014 and 53 lmol/l for sevuparin, and 12 and
89 lmol/l for tinzaparin. However, the values from the
one-site binding model (022 lmol/l for heparin,
073 lmol/l for sevuparin and 36 lmol/l for tinzaparin)
(Fig 2A) ease the comparison to previously published data.
These dissociation constants indicated that the P-selectin
binding pattern was better conserved in sevuparin than in
the LMWH tinzaparin, for which dissociation constants
were considerably higher.
Given that E-selectin-mediated adhesion also has been
implicated in SCD VOC, (Turhan et al, 2002; Hidalgo et al,
2009; Chang et al, 2010) we then extended our SPR
analyses to chimeras of all three selectins. Kd values were
determined using SPR measurements in which E-, P-, and
L-selectin chimeras were immobilized on a chip. Sevuparin
demonstrated high-affinity binding for both P-selectin
(38 nmol/l) and L-selectin (095 lmol/l) (Fig 2B), while the
Kd of sevuparin for E-selectin was 19 lmol/l (Fig 2B),
demonstrating that sevuparin bound to E-selectin with low
affinity.
Effect of sevuparin on SS-RBC adhesion to HUVECs
Given the promising results of the selectin binding profile,
we then measured the anti-adhesive properties of sevuparin
by employing a graduated height flow chamber to directly
measure RBC adhesion to cultured HUVECs that had been
stimulated with IL13 and histamine to upregulate P-selectin
expression. Overall, sevuparin inhibited SS-RBC adhesion to
these cells with a clear dose-dependent relationship (Fig 3A).
An effect became observable when sevuparin was used at
concentrations as low as 10 lg/ml, and at 50, 100, 200, 400
and 600 lg/ml, sevuparin had clear and significant effects
(P = 0006, 0006, 0001, 0037, 0001, respectively, using a
paired t-test in which patient samples were compared to tests
done in the absence of sevuparin using the same donor sam-
ples, see Fig 3A). Inhibition of adhesion was most effective
with higher sevuparin doses and in patients’ RBCs with
higher baseline adhesion. The differences in inhibition
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between highly adherent and only moderately adherent SS-
RBCs were statistically significantly different in the group
studied using 100 lg/ml sevuparin (P = 002, data not
shown). The capacity of sevuparin to inhibit neutrophil
adhesion to HUVECs was also assessed in the flow chamber
system; however, higher concentrations of sevuparin were
required to achieve significant inhibition of neutrophil adhe-
sion (Figure S1, Data S1). The inhibitory effect of sevuparin
on neutrophil adhesion was statistically significant at 400 lg/
ml, and the effect size continued to increase up to 800 lg/ml
in vitro.
P-selectin-mediated adhesion of SS-RBCs
Heparinoids have been previously shown to block P-selectin
(Matsui et al, 2002; Embury et al, 2004). Therefore, to con-
firm that P-selectin was involved in the adhesion events
observed in this study, monoclonal antibody (mAb) clone
9E1 (R&D Systems) was used to inhibit SS-RBC adhesion to
IL13+histamine-stimulated HUVECs. The mAb markedly
inhibited SS-RBC adhesion when concentrations of 75 lg/
ml and 10 lg/ml were used, with 10 lg/ml 9E1 mAb pro-
ducing a similar reduction in adhesion as was observed with
200 lg/ml sevuparin (Fig 3B).
Effect of sevuparin on SS-RBC adhesion and vaso-
occlusion in vivo
After confirming the anti-adhesive effect of sevuparin in the
in vitro assay, we sought to also assess its effect in vivo.
Therefore, sevuparin was studied in a mouse model with
both an anti-adhesion read-out and the crucial functional
read-out of restoring normal blood flow. The results show
that sevuparin markedly decreased the degree to which SS-
RBCs adhered to blood vessel walls in animals that had
been pretreated with TNFa. (Fig 4A, global analysis of vari-
ance P < 00001). Although the mean % occupancy
observed with a 40 mg/kg sevuparin dose was only slightly
lower than that observed with the 20 mg/kg dose, the dif-
ference between the doses was statistically significant
(P = 00459). When microvascular functionality (blood
flow) was investigated, sevuparin clearly demonstrated a
dose-dependent capacity to prevent vaso-occlusion, with
20 mg/kg given subcutaneously demonstrating maximal or
near-maximal effect. The read-out is given as the % of ves-
sels with normal flow, and here a much larger proportion
of vessels had normal blood flow after 20 mg/kg sevuparin
than after saline infusion as control (P = 00003, Fig 4B).
For this parameter, 40 mg/kg sevuparin led to a small and
(A)
(B)
Fig 2. Sevuparin interactions with selectins. (A) Binding of sevuparin, tinzaparin and unfractionated heparin to P-selectin. Binding was recorded
by SPR measurements with the heparinoids in solution binding to a P-selectin chimera that was attached to the chip. (B) Representative binding
curves of sevuparin binding to E-, P- and L-selectins. P-selectin: The Kd values were calculated based on sevuparin concentrations of 16, 63, and
25 lmol/l without CaCl2. L-selectin: The Kd values were calculated based on sevuparin concentrations of 16, 63, 25, and 100 lmol/l without
CaCl2. E-selectin: The Kd values were calculated based on sevuparin concentrations of 30–270 lmol/l without CaCl2.
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statistically non-significant improvement of blood flow
compared with 20 mg/kg sevuparin.
Comparison of the anti-adhesive effects of sevuparin and
tinzaparin
Considering the clinically interesting effects on VOC in SCD
observed with the LMWH tinzaparin, (Qari et al, 2007) a
direct comparison between the anti-adhesive activities of
sevuparin and tinzaparin was performed. When the capacity
of sevuparin and tinzaparin to inhibit SS-RBC adhesion to
endothelial cells in flow chambers in vitro was compared,
sevuparin and tinzaparin were equally effective in reducing
SS-RBC adhesion at 200 and 400 lg/ml compared with the
control (Fig 5A), although due to variability, the differences
for control versus sevuparin 400 lg/ml (P = 00593), did not
quite reach statistical significance.
Sevuparin and tinzaparin were also compared in the
in vivo model. Each drug reduced vessel occupancy by adher-
ent SS-RBCs to a similar degree at similar mg/kg doses
(Fig 5B); there were no significant differences between the
effects of sevuparin and tinzaparin at any dose. Indeed, the
effects exerted by the two compounds are not statistically sig-
nificantly different (vessel occupancy and blood flow, Fig 5B,
C), while the difference between control and drug treatment
was significant for all doses of both sevuparin and tinzaparin.
The dose-responses were compared with matched controls,
and a global statistical data analysis demonstrated that both
sevuparin and tinzaparin were able to prevent vaso-occlusion
in a dose-dependent manner (Fig 5C).
Target protein profiling
Taking together the initial selectin binding data and the anti-
adhesive effects demonstrated both in vitro and in vivo, it
could be hypothesized that sevuparin is also blocking addi-
tional adhesive interactions through more firm adhesion
events, possibly via other adhesion receptors. To address this
possibility, a second round of binding interaction studies was
performed. FCS was employed to further define the target
spectrum of sevuparin in a homogeneous format in solution.
The selectins were included in order to to relate these new
results to the previously generated data. For direct interac-
tion measurements with target proteins, fluorescein-labelled
sevuparin (fluo-sevuparin) was used, which had a diffusional
autocorrelation time of 78 ls, as expected for molecules of
this size. A degree of labelling of 02 per molecule was calcu-
lated by ultraviolet/Vis spectroscopy. At this low level of
labelling, a sufficient number of molecules carry a label to
allow detection, while the risk of interference with molecular
interactions due to multiple labels per molecule should be
minimal.
We investigated binding of sevuparin to selected cellular
adhesion mediators, including, P-, E- and L-selectins, VWF,
TSP and fibronectin (FN). For 1–2 different concentrations
of each potential target protein, fluo-sevuparin was titrated
over a concentration range of 5–350 nmol/l, and autocorrela-
tion functions were acquired for each sample. To assess
whether interactions changed over time, measurements were
conducted both directly after mixing and after a 3-h incuba-
tion period (Figures S2 and S3, Data S1). Binding of sevu-
parin to a target protein slows down diffusion, leading to the
appearance of a second component in the autocorrelation
function. Fitting of the autocorrelation functions with a two-
component model, in which one component corresponded
to the free and one to the bound sevuparin, yielded the frac-
tion of bound sevuparin. Based on the known concentrations
of binding partners in the sample, this was translated into
dissociation constants (Table SII, Data S1). E-selectin and
FN demonstrated the lowest capacity to bind sevuparin,
Fig 3. Effect of sevuparin and anti P-selectin monoclonal antibodies
on SS-RBC adhesion to HUVECs. (A) Dose response of sevuparin
concentration (lg/ml) versus number of adhesive events per mm2
between human SS-RBCs and activated HUVECs, during continuous
flow at 03 dynes/cm2. * indicates P < 005 compared to adhesion in
the absence of sevuparin. (N: IL13 and histamine only, 20. Sevuparin
10 lg/ml, 2; 50 lg/ml, 4; 100 lg/ml, 7; 200 lg, 6; 400 lg, 4; 600 lg,
3.) HUVECs were activated to increase P-selectin expression by IL13
and histamine treatment as described in Materials and methods. (B)
Comparison of the effect of sevuparin and anti-P-selectin antibodies
on SS-RBC adhesion to activated HUVECs. * indicates P < 005
compared to adhesion in the absence of sevuparin or mAb 9E1. (N:
IL13 and histamine only, 6. Sevuparin 100 lg/ml, 3; 200 lg/ml, 2.
9E1 mAb 75 lg/ml, 4; 10 lg/ml, 2.)
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although as expected, the fraction of bound ligand increased
with sevuparin concentration in both cases. Also as expected,
the dissociation constant, as determined from binding equi-
libria, was independent of the concentration of the labelled
sevuparin and the interactor concentration, except for VWF
(Figure S2). For VWF, lower dissociation constants were cal-
culated for higher labelled sevuparin concentrations. The rea-
son for this concentration dependence is not clear.
Dissociation constants were also determined by competi-
tive titration of fluorescently labelled sevuparin with unla-
belled sevuparin. Two different approaches were used to
determine dissociation constants in the presence of unla-
belled ligand. The first approach determined dissociation
constants for each individual sample as before for the total
sevuparin concentration (labelled and unlabelled in the sam-
ple, Figure S4, Data S1). The second approach employed the
Cheng–Prusoff equation to derive dissociation constants
from inhibitory constant (Ki) values for those ligands to
which binding of fluorescently labelled ligand could be fully
competed (Figures S5, S6 and S7, Data S1).
Overall, there was good accordance for dissociation con-
stants as determined in the absence (first approach, direct
titration) and presence of competitive inhibitor and derived
from the fraction of bound fluorescent sevuparin (Table I).
Also, the dissociation constants for the selectins were in the
same range as those determined with the one-site binding
model. FN had the highest dissociation constant, followed by
E-selectin. L- and P-selectins and VWF displayed low and
very similar dissociation constants. Thrombospondin A had
the lowest dissociation constant. Similar Kd values for hep-
arinoids have been documented elsewhere (Koenig et al,
1998; Barabino et al, 1999; Wang et al, 2002; Wang & Geng,
2003; Brittain et al, 2004; Simonis et al, 2007; Gayen Betal &
Setty, 2008).
Discussion
The results presented here support the hypothesis that sevu-
parin can improve vascular blood flow in SCD by binding to
several key cellular adhesion receptors and plasma compo-
nents that contribute to vaso-occlusion. Thus, our observa-
tions with sevuparin are both of potential clinical importance
as well as interesting from the point of view of understand-
ing SCD pathophysiology, as they support the role of anti-
adhesion therapy in counteracting the causative processes of
sickle cell adhesion and vaso-occlusion. Abnormal adhesion
between blood cells and the endothelium in SCD has been
linked to disease severity (Hebbel et al, 1980b; Setty & Stuart,
1996; Dworkis et al, 2011). Although the pathophysiology of
acute pain episodes is complex and not fully understood, a
cascade of cell adhesion events leading to vaso-occlusion and
ischemia has been convincingly demonstrated (Manwani &
Frenette, 2013). Therefore, inhibition of abnormal adhesion
should restore normal blood flow and thereby result in faster
pain relief and reduced tissue injury. Preclinical and early
phase clinical studies of various compounds that inhibit
Fig 4. Effect of sevuparin in vivo on SS-RBC adhesion to vessel walls. Microscopic observations of postcapillary venules were conducted through
implanted window chambers after infusion of SS-RBCs into the tail veins of nude mice using 209 magnification. (A) Dose response of sevuparin
concentration on vessel wall SS-RBC occupancy reflecting the anti-adhesive properties of sevuparin. The percentage of vessel length with diame-
ters up to 25 lm occupied by SS-RBCs was quantified as follows: % venular length occupied by SS-RBCs 9 (length of vessel wall with adherent
cells/total length of the vessel segments analysed) 9 100. Values are means of >30 vessels analysed for each mouse. Error bars show SEM of at
least 3 different experiments for each experimental condition. (B) Dose-dependent restoration of vascular function (blood flow) by sevuparin.
Sevuparin Reduces HbS RBC-Induced Vaso-Occlusion
ª 2016 John Wiley & Sons Ltd 941
British Journal of Haematology, 2016, 175, 935–948
diverse adhesive interactions further support this hypothesis
(Embury et al, 2004; Chang et al, 2008, 2010; Gutsaeva et al,
2011; Manwani et al, 2015; Telen et al, 2015).
Anticoagulation treatment for SCD has been investigated
in several studies (Salvaggio et al, 1963; Chaplin et al, 1989;
Ahmed et al, 2004; Qari et al, 2007). However, a substantial
proportion of patients with SCD are at clinical risk of haem-
orrhage, often due to intracerebral angiopathy, and especially
so-called Moyamoya abnormalities of the central nervous
system vasculature. This risk of haemorrhage has contributed
to some reluctance to adopt therapeutic anticoagulation
either in a prophylactic setting or during vaso-occlusive epi-
sodes (Qari et al, 2007). Ruling out the existence of vascular
abnormalities that predispose to intracerebral haemorrhage
prior to starting treatment would both be cost-prohibitive
and delay treatment. Thus, the pharmacological use of anti-
coagulation treatments remains of undefined risk and benefit
in the SCD population.
Heparin also interferes with P-selectin-mediated SS-RBC
adhesion to endothelial cells (Matsui et al, 2002). The data
Fig 5. Comparison of the anti-adhesive effects
of sevuparin and tinzaparin. (A) Effect of sevu-
parin compared with tinzaparin on SS-RBC
adhesion to HUVECs in vitro. Adhesive events
per mm2 were measured as previously
described. The relatively large differences in the
numbers of adhesive events between controls
(IL13 and histamine only) and samples in
which sevuparin or tinzaparin were used were
not uniformly statistically significant, and the
most significant difference was observed for
control versus 400 lg/ml sevuparin. Lack of
statistically significant differences between con-
trol and heparinoids was probably due to vari-
ability in adhesivity among patient samples.
(B) Effects of equivalent mg/kg sevuparin and
tinzaparin doses on vessel wall occupancy by
adherent SS-RBCs in vivo. Vessel occupancy is
defined as the % of the vessel wall occupied by
adherent, labelled human SS-RBCs. Global sta-
tistical analysis of all data by ANOVA demon-
strates that both sevuparin and tinzaparin can
prevent vaso-occlusion (P < 00001). There
was no statistically significant difference in the
effects of the two drugs. (For Panels B and C,
N = 4–11 for each dose of sevuparin and tinza-
parin except for tinzaparin 40 mg/kg, for
which N = 2.) (C) The effect of sevuparin in
mice in vivo, measured as vessel function. All
of the tested sevuparin and tinzaparin doses
were effective in improving vessel function
(number of flowing vessels) (P < 00001).
There were no statistically significant differ-
ences when results using equivalent doses of
sevuparin and tinzaparin were compared.
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for sevuparin presented here strongly suggest that blocking
abnormal cell adhesion represents a mechanism of action
deserving of more attention. In in vitro flow chamber experi-
ments, sevuparin was an effective inhibitor of SS-RBC adhe-
sion to endothelial cells. Interestingly, the degree of RBC
adhesion to endothelial cells varied among patients, confirm-
ing both our previous observations and those of others
(Hebbel et al, 1980b; Zennadi et al, 2004). Variability among
patients may be linked to both the expression of ligands on
the RBC for various endothelial cell adhesion receptors,
including P-selectin and integrin avb3, and their activation
state. Because the RBC ligand for P-selectin is currently
unidentified, it was not possible to test this directly. In addi-
tion, the activation state of erythroid adhesion receptors
probably varies among patients, as previously described (Zen
et al, 1999, 2004). Hydroxycarbamide can also affect both
adhesion receptor expression as well as adhesion receptor
activation, often in opposite directions (Gambero et al, 2007;
Odievre et al, 2008; Bartolucci et al, 2010; Chaar et al, 2014).
Nonetheless, vaso-occlusion, when it occurs, still occurs
through the same mechanisms, with and without hydroxy-
carbamide. This has recently been seen in the similar effect
of another anti-adhesive drug/selectin inhibitor, GMI-1070
(rivipansel), in the presence or absence of hydroxycarbamide
(Telen et al, 2015). In vivo, variability of both RBC and leu-
cocyte adhesion may also arise from genetic variability affect-
ing leucocytes and endothelial cells, including indirect effects
via inflammatory pathways. This, however, is less likely to be
a factor in syngeneic mice.
Our in vivo studies focused on human SS-RBCs to ensure
that the drug effects observed were relevant to human dis-
ease, because murine SS-RBCs, although reported to also
bind P-selectin, (Matsui et al, 2001, 2002) lack several known
RBC adhesion receptors, including BCAM/Lu and CD44,
(Sugimoto et al, 1994; Moulson et al, 2001) which are
involved in binding to laminin, FN and leucocytes (Verfaillie
et al, 1994; Udani et al, 1998; Zennadi et al, 2008). Nonethe-
less, at least two major murine endothelial receptors for
SS-RBC adhesion are similar enough to the human that
reagents that block human SS-RBC adhesion to murine
endothelium also block adhesion to human endothelial
receptors. Thus, heparins block SS-RBC binding to both
human and murine P-selectins (Matsui et al, 2001, 2002)
despite the lack in the murine P-selectin of one complement-
binding domain (Weller et al, 1992). Likewise, reagents that
block adhesion via the aVb3 integrin of endothelial cells do
so for both murine and human cells (Kaul & Hebbel, 2000;
Zennadi et al, 2004, 2007).
Although the chronic endotheliopathy and baseline leuco-
cyte activation of SCD is absent, this model system employs
TNF-induced activation of both endothelial cells and leuco-
cytes, has repeatedly been proven useful for studying SS-RBC
interactions with the endothelium and leucocytes in vivo, and
has produced results that have subsequently been replicated
in sickle mice and human studies (Zennadi et al, 2007, 2008,
2012; De Castro et al, 2012; Zennadi, 2014). As in similar
investigations, two assessments were performed: percentage
occupancy as a measure of abnormal adhesion of cells to
endothelium, as well as blood flow, which best measures the
degree of vaso-occlusion. Unless a vessel is quite narrow, it
takes more than one layer of adherent red cells to block
blood flow.
Sevuparin clearly demonstrated a dose-dependent capacity
to prevent vaso-occlusion, with 20 mg/kg given subcuta-
neously demonstrating maximal or near-maximal effect. This
effect was clearly related to inhibition of RBC adhesion to
the vessel walls, although inhibition of leucocyte adhesion
may also have contributed (Figure S1). Furthermore,
Table I. Comparison of dissociation constants as determined by FCS using three different analytic approaches.
Adhesion protein*
Kd Direct (lmol/l) Kd Titration (lmol/l)
IC50
(lmol/l)
Ki Cheng
Prusoff (lmol/l)Average SD Average SD
P-selectin –† – 0485 038 0942 0622
E-selectin 451 152 448 – –§ –§
L-selectin 5 lmol/l 0807 0309 0451 043 –§ –§
Fibronectin 651 244 225 0344 315 297
von Willebrand factor 0720‡ 0893‡ 0479 0126 645 455
Thrombospondin 0487‡ 0238‡ 0419 0180 497 297
Kd direct refers to averages of dissociation constants derived from binding equilibria with labelled ligand, where bound and free ligand were
obtained from two-component fits of the autocorrelation function. Kd titration refers to dissociation constants derived for binding equilibria in
the presence of unlabelled ligand. IC50 refers to the concentration of an inhibitor where the response (or binding) is reduced by half. Ki Cheng
Prusoff refers to dissociation constants that were determined for those binders where binding of labelled ligand could be fully competed with
unlabelled ligand. For determination of dissociation constants via Cheng Prusoff, an average of the Kd titration and the Kd direct was employed.
*Adhesion proteins were employed at the following concentrations: P-selectin 3 lmol/l, E-selectin 5 lmol/l, L-selectin 5 lmol/l, fibronectin
10 lmol/l, VWF 2 lmol/l, Thrombospondin 16 lmol/l.
†Not determined due to limited amount of material available.
‡1 lmol/l concentration was used for the direct Kd measurements.
§Not possible to calculate, due to failure to compete out the labelled ligand.
Sevuparin Reduces HbS RBC-Induced Vaso-Occlusion
ª 2016 John Wiley & Sons Ltd 943
British Journal of Haematology, 2016, 175, 935–948
sevuparin has effects similar to tinzaparin at comparable mg/
kg doses. Given that sevuparin has a confirmed low anticoag-
ulant effect (Lindgren et al, 2015) and because the dose-
response curves for sevuparin and tinzaparin are very similar
in our animal model of vaso-occlusion, we conclude that it
is primarily the anti-adhesive effect exerted by sevuparin and
tinzaparin rather than an anticoagulant effect that is most
important for prevention of vaso-occlusion by heparinoids.
Notably, sevuparin has no appreciable effect on bleeding
time, platelet activation or platelet adhesion.
Binding experiments with isolated potential adhesion
receptors suggest that multiple interactions contribute to the
anti-adhesive effect of sevuparin. Employing a combination
of two orthogonal methods to investigate binding interac-
tions, SPR and FCS, sevuparin demonstrated significant
binding to P-selectin, L-selectin, VWF, TSP and FN, but only
weak binding to E-selectin (Table S2). Compared with P-
selectin and L-selectin, there was only very weak binding to
E-selectin (Fig 2 and Figure S2). Sevuparin’s low or limited
affinity to E-selectin is in line with published data on heparin
(Koenig et al, 1998). Furthermore, SPR data support the
notion that sevuparin engages in multivalent binding, i.e.,
one sevuparin chain interacting with several P-selectin mole-
cules at the same time. In addition, the difference observed
in heparinoid-binding affinity to selectins when using lmol/l
or nmol/l levels of the ligand may reflect these multivalent
interactions; thus, when incubating at only nmol/l concentra-
tions, only the high-affinity site/interactions are detected,
while at lmol/l concentrations, the Kd values reflect a com-
bination of two or more interaction sites.
It is well-known that heparin has many pharmacological
properties other than its effect on anticoagulation (Mulloy
et al, 2016). However, less is known about the mechanisms
of these other activities. Here, we have used two different
methods to investigate the binding of sevuparin to previously
identified heparin-binding proteins known to contribute to
the abnormal adhesion seen in SCD. FN, VWF and TSP are
recognized as complex to study from a biochemical binding
perspective, as they can interact in multiple ways (multiva-
lent) and also form oligomers (Barabino et al, 1999; Tan &
Ginsburg, 2008). There are many similarities between hep-
arin’s polypharmacological anti-inflammatory mechanism
and sevuparin’s mechanism of action as elucidated here. It is
reasonable to speculate that sevuparin acts at several steps in
the cascade leading to vaso-occlusion, much like the complex
anti-inflammatory effects observed for heparin. For example,
by binding P- and L-selectin, sevuparin probably blocks the
initial rolling of blood cells on the endothelium. Then, firm
adhesion may be abrogated by sevuparin binding to the
bridging proteins VWF, FN and TSP, thus hindering the
interactions between integrins on the activated endothelium
and the blood cells.
Fig 6. Potential multimodal mechanism of sevuparin action. This figure demonstrates the potential interactions between SS-RBCs and the blood
vessel wall endothelium. See figure for explanation of respective symbols. FN, fibronectin; RBC, red blood cell; TSP, thrombospondin; VWF, von
Willebrand factor; WBC, white blood cell.
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To further understand which of the interactions would be
likely to be relevant in the clinical setting, a pharmacokinetic
bridge study was performed in mice (Table SIII, Data S1).
From this, the effective dose (which is 20 mg/kg in the
in vivo model) was translated into an effective target plasma
concentration of 20 lg/ml (corresponding to about
25 lmol/l). At this concentration, sevuparin would bind to
the adhesion proteins P-selectin, L-selectin, VWF, TSP and
(potentially) FN, while the interaction with E-selectin would
be limited (illustrated in Fig 6). The capability of sevuparin
to interact with several potential targets of SS-RBC adhesion
could be of critical importance in VOC, as blockade of mul-
tiple interactions is likely to be beneficial in interrupting
abnormal adhesion.
The capacity of sevuparin to prevent or reverse VOC and
the resulting pain in clinical use remains to be confirmed.
Clinical phase II studies have now been initiated
(https://clinicaltrials.gov/ct2/show/NCT02515838; https://
www.clinicaltrialsregister.eu/ctr-search/trial/2014-004416-11/
NL). Based on the proposed mechanism of action of sevu-
parin and the activity we have observed, we expect sevuparin
to be an effective new treatment for SCD patients who are
experiencing vaso-occlusive events.
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